Hematology

In instances when longer term or repeat treatment is required, continued use of IG should be based on objective measures of effectiveness established at the outset of treatment. These measures should be assessed no later than 6 months after initiation of treatment and at least annually thereafter. If clinical effectiveness has not been achieved, IG should be discontinued.

Acquired hemophilia

Not for Routine Use

Order Number: H14-AH

Acquired red cell aplasia

Not for Routine Use:
Order Number: H15-ARCA

Acquired von Willebrand’s disease (AvWD)

Not for Routine Use:
Order Number: H16-AvWD

Autoimmune hemolytic anemia (AIHA)

Not for Routine Use:
Order Number: H17-AIHA

Autoimmune neutropenia

Not for Routine Use:
Order Number: H18-AN

Fetal / Neonatal alloimmune thrombocytopenia (F/NAIT)

Recommended Indications in which IG can be used:
Order Number: H1-FAIT

Gestational alloimmune liver disease (GALD)/alloimmune neonatal hemochromatosis

Recommended Indications in which IG can be used:
Order Number: H3-GALD

Hematopoietic stem cell transplant (HSCT), allogeneic, Cytomegalovirus (CMV)-induced pneumonitis

Recommended Indications in which IG can be used:
Order Number: H7-HCST

Hematopoietic stem cell transplant (HSCT), allogeneic, graft-versus-host disease

Do Not Use

Hematopoietic stem cell transplant (HSCT), autologous

Do Not Use